Authorized purpose: Detection, localization, and quantification of mitral-annulus calcification on non-gated non-contrast chest CT.
Clinical role
Adjunctive measurement and quantification support; the output is informational and not intended for stand-alone use.
Images and patients
CT/CTA · Chest (Mitral Annulus) / Heart
Key limitation
Keep in mind: Output does not replace the original report or CT, is not stand-alone, and requires physician review. FDA notes that non-gated CT may have motion artifacts and scoring variability; the packet does not establish clinical outcomes or management benefit.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Detection, localization, and quantification of mitral-annulus calcification on non-gated non-contrast chest CT.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Chest (Mitral Annulus) / Heart Input: DICOM non-gated, non-contrast chest CT from adults aged 40 and older, with up to 5 mm slice thickness in the described technological comparison.
Who uses it?Intended users: Qualified medical professionals such as cardiologists or radiologists.
What does the software produce?Output: Binary detection at an Agatston-equivalent threshold of 0 AU, estimated mitral-annulus calcium burden up to 5,000 Agatston-equivalent units, and a circular ROI localizing the burden on a copy of the CT for viewing in a diagnostic image viewer or optional report.
What is its most important limitation?Key limitation: Output does not replace the original report or CT, is not stand-alone, and requires physician review. FDA notes that non-gated CT may have motion artifacts and scoring variability; the packet does not establish clinical outcomes or management benefit.
Clinical takeaway. Clinical role: Detection, localization, and quantification of mitral-annulus calcification on non-gated non-contrast chest CT.
Evidence takeaway. Evidence from the reviewed source record: FDA standalone retrospective study used a multi-site U.S. pivotal dataset and three annotators with majority-vote reference masks. Co-primary endpoint families were positive/negative agreement, precision and recall of the circular ROI, Bland-Altman agreement, and correlation. FDA reports bias -6.47 AU, agreement limits -399.57 to 386.64 AU, precision 0.885 (95% CI 0.848-0.919), and recall 0.867 (0.834-0.895). The FDA states these metrics represent agreement with non-gated CT reference measurements.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Detection, localization, and quantification of mitral-annulus calcification on non-gated non-contrast chest CT.
Binary detection at an Agatston-equivalent threshold of 0 AU, estimated mitral-annulus calcium burden up to 5,000 Agatston-equivalent units, and a circular ROI localizing the burden on a copy of the CT for viewing in a diagnostic image viewer or optional report.
Output does not replace the original report or CT, is not stand-alone, and requires physician review. FDA notes that non-gated CT may have motion artifacts and scoring variability; the packet does not establish clinical outcomes or management benefit.
FDA standalone retrospective study used a multi-site U.S. pivotal dataset and three annotators with majority-vote reference masks. Co-primary endpoint families were positive/negative agreement, precision and recall of the circular ROI, Bland-Altman agreement, and correlation. FDA reports bias -6.47 AU, agreement limits -399.57 to 386.64 AU, precision 0.885 (95% CI 0.848-0.919), and recall 0.867 (0.834-0.895). The FDA states these metrics represent agreement with non-gated CT reference measurements.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA standalone retrospective study used a multi-site U.S. pivotal dataset and three annotators with majority-vote reference masks. Co-primary endpoint families were positive/negative agreement, precision and recall of the circular ROI, Bland-Altman agreement, and correlation. FDA reports bias -6.47 AU, agreement limits -399.57 to 386.64 AU, precision 0.885 (95% CI 0.848-0.919), and recall 0.867 (0.834-0.895). The FDA states these metrics represent agreement with non-gated CT reference measurements.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Bunkerhill MAC regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K250662
IndependenceIndependence not established
K250662
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K250662. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM non-gated, non-contrast chest CT from adults aged 40 and older, with up to 5 mm slice thickness in the described technological comparison.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: DICOM CT input and visual/ROI output available as a separate PACS series, with optional report insertion or DICOM Secondary Capture; exact supported interfaces and versions are not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-08 ·
Returned objects
Source context, not route validation: Binary detection at an Agatston-equivalent threshold of 0 AU, estimated mitral-annulus calcium burden up to 5,000 Agatston-equivalent units, and a circular ROI localizing the burden on a copy of the CT for viewing in a diagnostic image viewer or optional report.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Binary detection at an Agatston-equivalent threshold of 0 AU, estimated mitral-annulus calcium burden up to 5,000 Agatston-equivalent units, and a circular ROI localizing the burden on a copy of the CT for viewing in a diagnostic image viewer or optional report.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
DICOM CT input and visual/ROI output available as a separate PACS series, with optional report insertion or DICOM Secondary Capture; exact supported interfaces and versions are not established.
Bunkerhill Health's website states SOC 2 Type II certification, HIPAA compliance and ISO/IEC 27001:2022 certification. Badges only: no scope, dates or controls are given. Vendor-wide.
Vendor-wide
Checked 2026-10-25
Vendor statement, not an attestation; exact-release scope is not established.
ACR AI Central provides an exact-submission model card for Bunkerhill MAC; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
23Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K250662 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Deployment: Not verified - checked 2026-09-08 - Exact FDA submission
The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.
Authorized purpose: Adjunctive opportunistic detection and quantification of aortic valve calcification during routine clinical-care chest CT review; a physician reviews the informational ROI and estimated calcium burden and decides any further action.
Authorized purpose: Web-based post-processing of cardiac CT data from CCTA performed for CAD or suspected CAD to view and analyze coronary plaques/atherosclerosis and stenosis and support measurement and visualization of coronary arteries.
Authorized purpose: vascuCAP analyzes contrast multidetector CT of arterial vessels to support atherosclerosis stratification with color maps, three-dimensional views, multiplanar reformats, and measurements for physician review.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.